{"id":"lorlatinib-with-chemotherapy-2","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"},{"drug":"Lapatinib","action":"Monitor","effect":"Increased risk of QT prolongation"}],"commonSideEffects":[],"contraindications":["Severe hepatic impairment (Child-Pugh C)","Concomitant use of strong CYP3A4 inhibitors","Concomitant use of strong CYP3A4 inducers","Pregnancy","Lactation"],"specialPopulations":{}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=lorlatinib-with-chemotherapy-2","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:55:02.139228+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:55:08.993729+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:55:02.162443+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=lorlatinib-with-chemotherapy-2","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:55:09.724064+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: EML4-ALK inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:55:11.032027+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3286830/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:55:10.936207+00:00"}},"allNames":"lorlatinib with chemotherapy 2","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Lorlatinib is an investigational therapy being developed by Pfizer for the treatment of non-small cell lung cancer (NSCLC) in combination with chemotherapy. It is a third-generation ALK inhibitor designed to overcome resistance to first and second-generation ALK inhibitors. The drug is currently in clinical trials and has shown promising results in early studies. However, it does not yet have an FDA label, indicating that it is still under review or has not been approved. Common side effects include peripheral neuropathy, hypercholesterolemia, and cognitive effects, among others. The drug's development is part of Pfizer's broader strategy to address unmet needs in NSCLC.","brandName":"Lorlatinib with chemotherapy 2","ecosystem":[],"isGeneric":true,"mechanism":{"target":"ALK","novelty":"Third-generation ALK inhibitor","modality":"Small molecule","drugClass":"ALK inhibitor","explanation":"","oneSentence":"","technicalDetail":"Lorlatinib binds to the ATP-binding site of ALK, preventing the kinase from phosphorylating its substrates and thereby blocking downstream signaling pathways that promote tumor growth and survival."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:42.634Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"","launchDate":null,"revenueYear":2025,"annualCostUS":"Generic pricing varies by manufacturer","annualRevenue":798,"genericStatus":"Generic — off-patent","revenueSource":"SEC 8-K Bristol-Myers Squibb (2026-02-05)","currentRevenue":"","revenueCurrency":"USD","patientPopulation":"Patients with ALK-positive NSCLC","peakSalesEstimate":"Not publicly reported","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:47:02.606798","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=lorlatinib-with-chemotherapy-2","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=lorlatinib-with-chemotherapy-2","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:55:12.901925+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Lobaplatin","company":"Teva Pharmaceuticals","advantage":"Lobaplatin is a platinum-based chemotherapy drug that competes with Lorlatinib in the ALK+ NSCLC treatment, offering a different mechanism of action.","genericName":"Lobaplatin"},{"name":"Pemetrexed","company":"Lilly","advantage":"Pemetrexed is a chemotherapy drug that competes with Lorlatinib in the treatment of non-small cell lung cancer (NSCLC), offering a different combination of mechanisms of action.","genericName":"Pemetrexed"},{"name":"Gemcitabine","company":"Pfizer","advantage":"Gemcitabine is a chemotherapy drug that competes with Lorlatinib in the treatment of non-small cell lung cancer (NSCLC), offering a different mechanism of action.","genericName":"Gemcitabine"}],"genericName":"lorlatinib-with-chemotherapy-2","indications":{"approved":[{"name":"Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) with brain metastases","regulator":"FDA"},{"name":"ALK-positive metastatic NSCLC without brain metastases","regulator":"FDA"},{"name":"ALK-positive metastatic NSCLC with brain metastases and with or without echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) fusion","regulator":"FDA"}],"offLabel":[],"pipeline":["Non-small cell lung cancer (NSCLC)"]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06333899","phase":"EARLY_PHASE1","title":"Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2025-08-03","conditions":"High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma","enrollment":15}],"_emaApprovals":[{"date":"","name":"Lorlatinib with chemotherapy 2","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":true,"chemblId":"CHEMBL3286830","moleculeType":"Small molecule","molecularWeight":"406.42"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL3286830"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-01 10:47:02.629581+00","biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:55:12.901925+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}